



Viatriis works to create sustainable access to medicine by delivering quality medicines at scale to people, regardless of geography or circumstance, through our extensive portfolio of medicines, a global, flexible and agile supply chain, and scientific expertise.

Viatriis was founded in 2020. Here are some of the highlights from our *five years of progress*:*

▶ Supplied >420 billion doses of medicine	▶ ~3,550 global product approvals
▶ ~115 billion doses of medicine on the WHO Essential Medicines List (EML)	▶ ~3,900 regulatory filings, including ~1,800 individual market submissions for Emerging and Expansion markets
▶ Helped enable treatment access for >300,000 patients living with drug resistant TB globally**	▶ In India, provided TB screening for >1.5 million people

*2020-2025
**November 2019 to January 2026

Resilient Supply Chains for Global Access

Our global supply chain – with its scale, resilience, and well-established efficiencies – remains a strong model for ensuring reliable access to medicines for patients everywhere. No single country produces all the medicines it needs, and no medicine is manufactured in every country.

As an essential business, Viatriis has taken actions to maintain a reliable supply of medicines, with special measures around critical medicines in times of volatile demand. Our ability to supply medicines and maintain high levels of service around the world is rooted in our global network of suppliers with a robust ability to manage shocks affecting any particular country or region. Our network allows us to offset risk and build resilience.

With more than 70 billion doses sold to customers in more than 165 countries and territories, our global customer service level in 2025 was 92%.¹

Building Access to NCD Prevention, Treatment, and Care

Noncommunicable diseases (NCDs) are long-lasting conditions caused by a mix of genetic, physiological, environmental, and behavioral factors.² NCDs including cardiovascular diseases, chronic respiratory diseases, cancer and diabetes, are the leading causes of death worldwide, with people in low- and middle-income countries disproportionately affected.³ Our broad portfolio addresses a wide range of therapeutic areas, including many of the high burden NCDs.

Some examples of our work to expand access to treatments in 2025 include product approvals in countries such as the UAE, Türkiye, the UK, South Korea and Japan to address a variety of therapeutic areas including cardiovascular diseases, pain, ophthalmology, and respiratory diseases.

Our Reach in 2025

Supplied medicines to ~1B patients around the world⁴

Sold >70 billion doses of medicine across >165 countries and territories

Supplied approximately half of the >200 molecules listed on the EU Critical Medicines List

Supplied >260 medicines on the WHO Essential Medicines List (EML), representing approximately 50% of the total list

Supplied medicines to >90% of low- and lower-middle-income countries

Provided 49 products on the WHO Prequalification of Medicines List

Supplied >135 medicines on the WHO Essential Medicines List for Children, representing >35% of the total list

Supplied products to 85% of the countries defined as Access Countries by the Access to Medicine Foundation

We continued our dedicated work with partners across the world to empower healthcare workers to contribute to more resilient healthier systems. In 2025, we provided healthcare workers with learning resources, including the Viatris Connect Medical portal and the multipartner-enabled NCD Academy, designed to help strengthen local standards of care.

Strengthening Infectious Disease Prevention, Diagnosis and Treatment

Viатris has a long-standing legacy in the collective efforts globally to help ensure the availability of essential infectious disease treatments, support public health initiatives and address unmet medical needs in disease management. We collaborate with global and local partners, including healthcare organizations, global procurement organizations, other pharmaceutical companies and governments, to enhance access to therapies and last mile deliveries and improve health outcomes.

- ▶ Viatris has more than **700 registrations** of infectious disease products across low- and middle-income countries
- ▶ We have **licensing agreements for 16 products** for HIV, hepatitis C and other infectious diseases with the Medicines Patent Pool (MPP). Our licensing partners include Gilead, Viiv Healthcare, MSD, TB Alliance and Otsuka.
- ▶ Approximately **16% of the world's adults and 45% of the world's children** on treatment for HIV use a Viatris product.

Viatris works with partners around the world to give patients the tools they need to take charge of their health, empowering patients and enhancing access to care.

Addressing Antimicrobial Resistance

Antimicrobial resistance (AMR) is a significant global health challenge. One in six bacterial infections globally is now resistant to antibiotics, and AMR could cause 10 million deaths each year by 2050. AMR occurs when microorganisms such as bacteria, viruses, fungi, and parasites evolve to resist the effects of antimicrobial drugs that were once effective against them. This makes infections, if not mitigated, harder to treat by reducing the effectiveness of treatments and increases the risk of disease spread, severe illness and even death.

Viatris takes a multi-pronged approach to actively engage in addressing AMR, both by providing access through our portfolio of more than 90 antimicrobials and in partnership with others.

Our HIV Treatment Access Goal

Our Goal: Provide ARV therapy equivalent to a total of 30 million patients, including >2 million children living with HIV/AIDS, between 2022 and the end of 2025.*

Our Progress: In 2025**, we provided treatments for ~4.5 million patients, including ~281,000 children living with HIV/AIDS. Since 2022, we have provided treatments for >28.1 million patients, including >1.8 million children.

Our HCP Access Goal

Our Goal: Impact 100 million patients via HCP education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025.

Our Progress: Through the end of 2025, NCD Academy is estimated to have impacted >175 million patients by providing primary care clinicians around the globe with essential education and best practices for managing NCDs.⁵

*Our ability to make progress on our goal depends on several factors, some of which are outside of our control, including the existence and funding of our distribution partners.
** The remediation activities at the Indore site have impacted our ARV therapy supply.

We are a founding member and active board member of the AMR Industry Alliance (AMRIA), the largest life sciences coalition, with over 100 biotech, diagnostics, generics, and research-based pharmaceutical companies and associations joining forces to provide sustainable solutions to curb AMR globally. We also serve as co-chair of the AMRIA Access and Appropriate Use Working group and are a member of the AMRIA Manufacturing Working Group.

Policy Solutions to Reduce Barriers to Access and Support Strong Health Systems

Most people will need many types of medicine over the course of their lifetime, for acute and chronic conditions, both infectious and non-communicable. Public policies are central factors in enabling availability of and access to these medicines at the right time, in the right place. We see an important role for a company like Viatris to leverage our broad portfolio, global presence and experiences, scientific expertise, and operations knowledge to support policymakers in identifying policies that advance access to quality medicines and build systems that sustain availability while minimizing unintended consequences. Around the world, Viatris is a member of 195 associations, with leadership roles in 47.

¹ Our customer service level metric is on-time in-full (OTIF) delivery to our customers. On-time is customer specific and measured against customer agreements. In-full is 100% of volume ordered.

² Burden of non-communicable diseases in China and its province

³ Noncommunicable Diseases

⁴ See 2025 Sustainability report, p. 6 for methodology.

⁵ Patient reach is calculated at an individual HCP learner level by multiplying the number of patients treated per week, as self-reported by the individual HCP learner upon registering for NCD Academy, by the number of weeks the individual was enrolled in NCD Academy (in some cases, multiple years). Patient reach for each individual learner is summed to arrive at total patient reach. Patient reach includes unique patients as well as repeat patient encounters.

Stay Connected

Media Relations
+1.724.514.1968
Communications@viatris.com

Investor Relations
+1.724.514.1813
InvestorRelations@viatris.com

